A detailed history of Orbimed Advisors LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 387,000 shares of PCVX stock, worth $33.5 Million. This represents 1.04% of its overall portfolio holdings.

Number of Shares
387,000
Previous 795,900 51.38%
Holding current value
$33.5 Million
Previous $60.1 Million 26.48%
% of portfolio
1.04%
Previous 1.45%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$70.52 - $117.12 $28.8 Million - $47.9 Million
-408,900 Reduced 51.38%
387,000 $44.2 Million
Q2 2024

Aug 14, 2024

SELL
$60.06 - $78.77 $16.2 Million - $21.3 Million
-270,231 Reduced 25.35%
795,900 $60.1 Million
Q1 2024

May 15, 2024

SELL
$59.79 - $81.05 $5.2 Million - $7.05 Million
-86,960 Reduced 7.54%
1,066,131 $72.8 Million
Q4 2023

Feb 14, 2024

BUY
$45.35 - $63.41 $6.62 Million - $9.25 Million
145,943 Added 14.49%
1,153,091 $72.4 Million
Q2 2023

Aug 14, 2023

BUY
$34.66 - $54.07 $9.63 Million - $15 Million
277,709 Added 38.07%
1,007,148 $50.3 Million
Q1 2023

May 15, 2023

SELL
$36.27 - $47.2 $20.1 Million - $26.1 Million
-553,687 Reduced 43.15%
729,439 $27.3 Million
Q4 2022

Feb 14, 2023

BUY
$20.58 - $47.95 $11.6 Million - $27.1 Million
565,226 Added 78.73%
1,283,126 $61.5 Million
Q3 2022

Nov 14, 2022

SELL
$21.69 - $28.53 $17.3 Million - $22.7 Million
-795,759 Reduced 52.57%
717,900 $17.2 Million
Q1 2022

May 16, 2022

BUY
$17.46 - $26.36 $7.28 Million - $11 Million
416,959 Added 38.02%
1,513,659 $36.6 Million
Q4 2021

Feb 14, 2022

BUY
$19.32 - $26.45 $1.2 Million - $1.64 Million
62,035 Added 6.0%
1,096,700 $26.1 Million
Q3 2021

Nov 15, 2021

BUY
$20.26 - $26.97 $1.81 Million - $2.41 Million
89,265 Added 9.44%
1,034,665 $26.2 Million
Q2 2021

Aug 16, 2021

BUY
$16.45 - $24.06 $4.88 Million - $7.14 Million
296,626 Added 45.72%
945,400 $21.3 Million
Q1 2021

May 17, 2021

BUY
$18.66 - $29.16 $345,471 - $539,868
18,514 Added 2.94%
648,774 $12.8 Million
Q4 2020

Feb 16, 2021

SELL
$26.57 - $51.74 $278,985 - $543,270
-10,500 Reduced 1.64%
630,260 $16.7 Million
Q3 2020

Nov 16, 2020

SELL
$26.5 - $55.4 $5.54 Million - $11.6 Million
-209,240 Reduced 24.62%
640,760 $31.6 Million
Q2 2020

Aug 14, 2020

BUY
$26.15 - $35.45 $22.2 Million - $30.1 Million
850,000 New
850,000 $26.9 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.13B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.